merck keytruda - Search News

News

Merck, Delaware

The Wall Street Journal on MSN · 1d

Merck to Spend $1 Billion on New Factory to Make U.S. Supplies of Blockbuster Drug

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

The Philadelphia Inquirer on MSN · 9h

Merck plans to move manufacturing of its biggest drug, Keytruda, to a new U.S. factory and lab in Delaware

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its best-selling cancer drug Keytruda to the U.S. and speed future drugs to market. Keytruda is currently made in Ireland and by contract manufacturers in the United States.

The American Bazaar · 1h

Pharmaceutical company Merck to invest $1 billion in Delaware plant

Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it prepares to deal with President Donald Trump's tariffs

Fierce Pharma2d

AACR: Merck's Keytruda prevents head and neck cancer from returning in industry-first win

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

Merck Faces Patent Lawsuit Over Easier-to-Use Keytruda

A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...

STAT1d

Pharmalittle: We’re reading about FDA chaos delaying a rare disease drug, Merck’s U.S. investment, and more

Merck will grow its U.S. manufacturing footprint with a $1 billion plant, making it the latest drugmaker to invest in the U.S ...

Devdiscourse10h

Breakthrough in Cancer Treatments: Zongertinib, Jemperli, and Keytruda Making Waves

Exciting developments in cancer treatment were unveiled at the AACR meeting. Boehringer Ingelheim's zongertinib shows a 71% ...

Does Merck Stock Have Room For Growth?

The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...

STAT5d

Akeso wins Chinese approval for cancer drug positioned to rival Merck’s Keytruda

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this ...

Merck (NYSE:MRK) Presents Promising KEYTRUDA Trial Data at AACR 2025 Meeting

Merck (NYSE:MRK) recently announced promising results from its Phase 3 KEYNOTE-689 trial of KEYTRUDA, presented at the AACR Annual Meeting, which seems likely to have bolstered investor confidence, ...

Fierce Pharma6d

Halozyme sues Merck over subcutaneous Keytruda as licensing talks fall through

Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results